Asymptomatic microscopic colitis induced by secukinumab.
作者信息
Megna Matteo, De Lucia Mario, Fornaro Luigi, Tommasino Nello, Castiglione Fabiana, Cacciapuoti Sara, Testa Anna
机构信息
Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Gastroenterology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
出版信息
JAAD Case Rep. 2024 Apr 9;48:11-13. doi: 10.1016/j.jdcr.2024.03.017. eCollection 2024 Jun.
Abstract
摘要
相似文献
1
Asymptomatic microscopic colitis induced by secukinumab.司库奇尤单抗诱导的无症状性微观性结肠炎。
JAAD Case Rep. 2024 Apr 9;48:11-13. doi: 10.1016/j.jdcr.2024.03.017. eCollection 2024 Jun.
2
Secukinumab-Induced Lymphocytic Colitis.司库奇尤单抗相关淋巴细胞性结肠炎。
J Investig Med High Impact Case Rep. 2022 Jan-Dec;10:23247096221110399. doi: 10.1177/23247096221110399.
3
New onset inflammatory bowel disease in patient treated with secukinumab: Case report and review of literature.使用司库奇尤单抗治疗后新发病的炎症性肠病：病例报告及文献复习。
Dermatol Ther. 2021 Nov;34(6):e15151. doi: 10.1111/dth.15151. Epub 2021 Oct 13.
4
New-Onset Collagenous Colitis in a Patient With Psoriatic Arthritis: Can It Be Secukinumab?一名银屑病关节炎患者新发胶原性结肠炎：会是司库奇尤单抗所致吗？
Cureus. 2021 Jul 3;13(7):e16147. doi: 10.7759/cureus.16147. eCollection 2021 Jul.
5
IκBζ is a key player in the antipsoriatic effects of secukinumab.IκBζ 是司库奇尤单抗抗银屑病作用的关键因子。
J Allergy Clin Immunol. 2020 Jan;145(1):379-390. doi: 10.1016/j.jaci.2019.09.029. Epub 2019 Oct 14.
6
IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis.司库奇尤单抗抑制白介素-17A 可诱导银屑病的早期临床、组织病理学和分子缓解。
J Allergy Clin Immunol. 2019 Sep;144(3):750-763. doi: 10.1016/j.jaci.2019.04.029. Epub 2019 May 24.
7
Gut Microbiome in Psoriasis is Perturbed Differently During Secukinumab and Ustekinumab Therapy and Associated with Response to Treatment.银屑病患者肠道微生物组在司库奇尤单抗和乌司奴单抗治疗期间发生不同程度的紊乱，并与治疗反应相关。
Clin Drug Investig. 2019 Dec;39(12):1195-1203. doi: 10.1007/s40261-019-00849-7.
8
and other HLA-C alleles, as well as and genetic variants associate with optimal response to anti-IL-17A treatment in patients with psoriasis.以及其他 HLA-C 等位基因，以及 和 遗传变异与银屑病患者对抗 IL-17A 治疗的最佳反应相关。
Expert Opin Biol Ther. 2021 Feb;21(2):259-270. doi: 10.1080/14712598.2021.1862082. Epub 2020 Dec 28.
9
Asymptomatic Crohn's disease identified in a patient being treated with secukinumab: A case report.在接受司库奇尤单抗治疗的患者中发现无症状克罗恩病：一例报告。
SAGE Open Med Case Rep. 2019 Dec 6;7:2050313X19893580. doi: 10.1177/2050313X19893580. eCollection 2019.
10
Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study.司库奇尤单抗在日本中重度斑块状银屑病患者中的疗效和安全性：来自ERASURE（一项随机、安慰剂对照的3期研究）的亚组分析
J Dermatol. 2014 Dec;41(12):1039-46. doi: 10.1111/1346-8138.12668. Epub 2014 Oct 30.
引用本文的文献
1
Clinical features, treatment, and prognosis of secukinumab-induced inflammatory bowel disease.司库奇尤单抗诱导的炎症性肠病的临床特征、治疗及预后
Eur J Med Res. 2025 Jan 19;30(1):37. doi: 10.1186/s40001-025-02295-y.
本文引用的文献
1
Secukinumab-Induced Lymphocytic Colitis.司库奇尤单抗相关淋巴细胞性结肠炎。
J Investig Med High Impact Case Rep. 2022 Jan-Dec;10:23247096221110399. doi: 10.1177/23247096221110399.
2
Microscopic colitis.显微镜结肠炎。
Nat Rev Dis Primers. 2021 Jun 10;7(1):39. doi: 10.1038/s41572-021-00273-2.
3
IL-17 Inhibitors and Inflammatory Bowel Diseases: A Postmarketing Study in Vigibase.白细胞介素-17抑制剂与炎症性肠病：Vigibase中的一项上市后研究
Clin Pharmacol Ther. 2021 Jul;110(1):159-168. doi: 10.1002/cpt.2155. Epub 2021 Feb 12.
4
Secukinumab-Induced Inflammatory Bowel Disease in a Patient Treated for Chronic Plaque Psoriasis and Psoriatic Arthritis: A Case Report and Review of the Role of Novel Biologic Agents Targeting the p19 Subunit of IL-23.司库奇尤单抗治疗慢性斑块状银屑病和银屑病关节炎患者引发炎症性肠病：一例报告及靶向白细胞介素-23 p19亚基新型生物制剂作用的综述
Case Rep Med. 2020 Jul 24;2020:9404505. doi: 10.1155/2020/9404505. eCollection 2020.
5
Paradoxical gastrointestinal effects of interleukin-17 blockers.白介素-17 阻滞剂的矛盾性胃肠道作用。
Ann Rheum Dis. 2020 Sep;79(9):1132-1138. doi: 10.1136/annrheumdis-2020-217927. Epub 2020 Jul 21.
6
Systematic review with meta-analysis: risk of new onset IBD with the use of anti-interleukin-17 agents.系统评价与荟萃分析：抗白细胞介素-17 药物治疗的新发炎症性肠病风险。
Aliment Pharmacol Ther. 2019 Aug;50(4):373-385. doi: 10.1111/apt.15397. Epub 2019 Jul 15.
7
Inflammatory Bowel Disease Onset During Secukinumab Treatment: Real Concern or Just an Expression of Dysregulated Immune Response?在司库珠单抗治疗期间出现炎症性肠病：真的令人担忧，还是仅仅是免疫反应失调的表现？
Clin Drug Investig. 2019 Aug;39(8):799-803. doi: 10.1007/s40261-019-00803-7.
8
Microscopic colitis: pathophysiology and clinical management.显微镜结肠炎：病理生理学与临床管理。
Lancet Gastroenterol Hepatol. 2019 Apr;4(4):305-314. doi: 10.1016/S2468-1253(19)30048-2.
9
Histology of microscopic colitis-review with a practical approach for pathologists.显微镜下结肠炎的组织学——给病理学家的实用方法综述
Histopathology. 2015 Apr;66(5):613-26. doi: 10.1111/his.12592. Epub 2015 Jan 12.
10
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.司库奇尤单抗，一种人源抗白细胞介素-17A 单克隆抗体，用于中重度克罗恩病：一项随机、双盲、安慰剂对照试验的意外结果。
Gut. 2012 Dec;61(12):1693-700. doi: 10.1136/gutjnl-2011-301668. Epub 2012 May 17.
Zotero 插件